Dixon B, Bagnall D A, Speakman H
Br J Cancer. 1986 Dec;54(6):999-1008. doi: 10.1038/bjc.1986.272.
We report data on the transplantation of primary tumour cells and of lymph nodes containing metastatic cells disseminated by a mammary carcinoma (LMC1) implanted s.c. in the Johns' Strain Wistar rat. A new method is described for deriving the TD50 of metastatic cells and for comparing their lymphnodal clonogenicity in the transplanted and the original, i.e. 'primary' tumour host. The TD50 for transplanted primary LMC1 cells was approximately 12 (fiducial limits 8-20 cells), and the latency of the 8-10mm tumours formed (T8-10) after inocula of 10(2) to 10(5) cells decreased linearly with the logarithmic increase in the number of cells injected. From the T8-10 and tumour incidence data for transplanted inguinal, axillary and para-aortic nodes, the TD50 for metastatic cells was calculated to be 1120 cells (fiducial limits 790-1603 cells) indicating that the clonogenicity of naturally disseminated metastatic cells was about a 100 fold lower than that determined for transplanted primary tumour cells. The incidence and T8-10 data for axillary, inguinal and para-aortic lymph node metastases in primary-tumour-excised hosts suggests that, although metastatic cells may continue translymphnodal dissemination in situ, their TD50 is still consistent with that determined by node transplantation.
我们报告了关于原发性肿瘤细胞以及含有由皮下植入约翰氏品系Wistar大鼠的乳腺癌(LMC1)播散的转移细胞的淋巴结移植的数据。描述了一种新方法,用于推导转移细胞的半数致死剂量(TD50),并比较其在移植的和原始的,即“原发性”肿瘤宿主中的淋巴结克隆形成能力。移植的原发性LMC1细胞的TD50约为12(置信限8 - 20个细胞),接种10²至10⁵个细胞后形成8 - 10mm肿瘤(T8 - 10)的潜伏期随注射细胞数的对数增加呈线性下降。根据移植的腹股沟、腋窝和腹主动脉旁淋巴结的T8 - 10和肿瘤发生率数据,计算出转移细胞的TD50为1120个细胞(置信限790 - 1603个细胞),这表明自然播散的转移细胞的克隆形成能力比移植的原发性肿瘤细胞低约100倍。原发性肿瘤切除宿主中腋窝、腹股沟和腹主动脉旁淋巴结转移的发生率和T8 - 10数据表明,尽管转移细胞可能在原位继续进行经淋巴结播散,但其TD50仍与通过淋巴结移植确定的一致。